Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of “Hold” by Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has received a consensus rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $4.75.

Several research analysts have weighed in on IPSC shares. Leerink Partners set a $2.00 price target on shares of Century Therapeutics and gave the stock a “market perform” rating in a research report on Friday, March 13th. Mizuho started coverage on Century Therapeutics in a research note on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price objective for the company. Zacks Research cut Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 12th. Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, HC Wainwright upped their price target on Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st.

Institutional Investors Weigh In On Century Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Venture Management LLC purchased a new position in Century Therapeutics during the first quarter valued at approximately $27,495,000. Commodore Capital LP purchased a new stake in shares of Century Therapeutics in the first quarter worth $19,652,000. Seven Fleet Capital Management LP purchased a new stake in shares of Century Therapeutics in the first quarter worth $9,826,000. Spruce Street Capital LP raised its position in shares of Century Therapeutics by 185.5% during the 1st quarter. Spruce Street Capital LP now owns 4,059,054 shares of the company’s stock valued at $9,173,000 after purchasing an additional 2,637,522 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Century Therapeutics during the 4th quarter valued at $1,829,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Stock Down 4.9%

Century Therapeutics stock opened at $2.31 on Friday. The business has a 50-day simple moving average of $2.29 and a two-hundred day simple moving average of $2.12. The company has a market cap of $416.61 million, a P/E ratio of -2.03 and a beta of 1.55. Century Therapeutics has a 52-week low of $0.44 and a 52-week high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. Research analysts anticipate that Century Therapeutics will post -0.43 EPS for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.